Over 3.2M new cancer cases and 1.7M cancer-related deaths are registered in Europe every year. Current diagnostic methods are not sensitive enough, limiting the potential for early disease identification. Earlier detection and more precise diagnosis of disease will provide patients with the correct therapies at an earlier stage in the disease development. New innovations in nano medicine can help to reduce morbidity and mortality in the 21st century by the early detection, monitoring and fast treatment of chronic disease. The NAMDIATREAM project aims to provide new knowledge and expertise for biomedically relevant applications in the early diagnosis and imaging of cancer.
Cellix Value Add
Cellix ltd which spun out of Trinity in 2006 has greatly benefited from participation in the FP7 NAMDIATREAM pan-european consortium in terms of research expansion into cancer diagnostics and screening. The company has also benefited from the collaborative nature of the work carried out with the Multinationals and high-tech SMEs around new nanotechnological solutions
Trinity Value Add
NAMDIATREAM was formed to develop a nanotechnology based toolkit to enable early detection and imaging of molecular biomarkers for the most common cancer types, as well as permitting the identification of early-stage onset. The project is built on the innovative technology concepts of super-sensitive "lab-on-a-bead", "lab-on-a-chip" and "lab-on-a-wire" nano-devices. Prof. Yuri Volkov in the School of Medicine & CRANN coordinates the consortium and brings expertise in the areas of nanotoxicology and nanomedicine. Prof. Coey, School of Physics and Prof. Gun'ko from the School of Chemistry bring expertise in magnetic sensor and functionally labelled nanoparticles and nanowires.
Critical Trinity Enablers
The programme is built upon the extended range of clinically accepted multimodal nanomaterial for plasmonic, photolumiscence, non-centrosymmmetric and multimodal magnetic materials. New facilities have been created with the specific focus to translate NAMDIATREAM nanodiagnostics and nanomedicine outcomes into industrial products.
EU FP7 project under the Nanosciences, Nanotechnologies, Materials and new Production Technologies area. NAMDIATREAM is a €13m project of which €3.9m will be directly invested in Ireland. It brings together an international consortium of 7 high-tech SMEs including Irish SMEs Cellix Ltd and Radisens Diagnostics Ltd, 2 multinational companies (Becton Dickinson, Europe and Nikon Instruments, France), 12 academic institutions and 1 technology transfer company. Researchers from the School of Medicine and CRANN, Trinity's nanoscience research institute, are leading the technical programme and have overall responsibility for coordinating the consortium programme.
"Through the NAMDIATREAM project, Cellix has developed a relationship with BD and the resulting expertise which Cellix has gained in the field of flow cytometry is proving commercially important in terms of Cellix's engagement with OEM customers for defined applications"
Vivienne Williams, CEO, Director and Founder, Cellix Ltd.